CNS Disorders  >>  Plivensia (sirukumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Plivensia (sirukumab) / J&J
NCT02473289 / 2014-005206-37: An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

Completed
2
193
Canada, US, Europe, RoW
Sirukumab 50 mg, Placebo
Janssen Research & Development, LLC
Depressive Disorder, Major
05/18
05/18

Download Options